These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 26588898)

  • 21. Barriers to HIV Cure.
    Stein J; Storcksdieck Genannt Bonsmann M; Streeck H
    HLA; 2016 Oct; 88(4):155-63. PubMed ID: 27620852
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Experimental Systems for Measuring HIV Latency and Reactivation.
    Fujinaga K; Cary DC
    Viruses; 2020 Nov; 12(11):. PubMed ID: 33182414
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ingenol derivates promising for HIV eradication.
    Poveda E
    AIDS Rev; 2014; 16(4):246. PubMed ID: 25373349
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The challenge of viral reservoirs in HIV-1 infection.
    Blankson JN; Persaud D; Siliciano RF
    Annu Rev Med; 2002; 53():557-93. PubMed ID: 11818490
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus.
    Chun TW; Justement JS; Moir S; Hallahan CW; Maenza J; Mullins JI; Collier AC; Corey L; Fauci AS
    J Infect Dis; 2007 Jun; 195(12):1762-4. PubMed ID: 17492591
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Attacking the HIV reservoir from the immune and viral perspective.
    Massanella M; Martinez-Picado J; Blanco J
    Curr HIV/AIDS Rep; 2013 Mar; 10(1):33-41. PubMed ID: 23242702
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Barriers for HIV Cure: The Latent Reservoir.
    Castro-Gonzalez S; Colomer-Lluch M; Serra-Moreno R
    AIDS Res Hum Retroviruses; 2018 Sep; 34(9):739-759. PubMed ID: 30056745
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Scientific rationale for antiretroviral therapy in 2005: viral reservoirs and resistance evolution.
    Siliciano RF
    Top HIV Med; 2005; 13(3):96-100. PubMed ID: 16170226
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Alphabet Soup of HIV Reservoir Markers.
    Sharaf RR; Li JZ
    Curr HIV/AIDS Rep; 2017 Apr; 14(2):72-81. PubMed ID: 28401492
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New Insights into HIV-1 Persistence in Sanctuary Sites During Antiretroviral Therapy.
    Poveda E; Tabernilla A
    AIDS Rev; 2016; 18(1):55. PubMed ID: 27028272
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Molecular Biology of HIV Latency.
    Khoury G; Darcis G; Lee MY; Bouchat S; Van Driessche B; Purcell DFJ; Van Lint C
    Adv Exp Med Biol; 2018; 1075():187-212. PubMed ID: 30030794
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The development of immune-modulating compounds to disrupt HIV latency.
    Remoli AL; Marsili G; Battistini A; Sgarbanti M
    Cytokine Growth Factor Rev; 2012; 23(4-5):159-72. PubMed ID: 22766356
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Challenges and Promise of Human Immunodeficiency Virus Remission.
    Li Y; Mohammadi A; Li JZ
    J Infect Dis; 2021 Feb; 223(12 Suppl 2):4-12. PubMed ID: 33586773
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection.
    Tsai P; Wu G; Baker CE; Thayer WO; Spagnuolo RA; Sanchez R; Barrett S; Howell B; Margolis D; Hazuda DJ; Archin NM; Garcia JV
    Retrovirology; 2016 May; 13(1):36. PubMed ID: 27206407
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIV eradication: combinatorial approaches to activate latent viruses.
    De Crignis E; Mahmoudi T
    Viruses; 2014 Nov; 6(11):4581-608. PubMed ID: 25421889
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Probabilistic control of HIV latency and transactivation by the Tat gene circuit.
    Cao Y; Lei X; Ribeiro RM; Perelson AS; Liang J
    Proc Natl Acad Sci U S A; 2018 Dec; 115(49):12453-12458. PubMed ID: 30455316
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Use of Toll-Like Receptor Agonists in HIV-1 Cure Strategies.
    Martinsen JT; Gunst JD; Højen JF; Tolstrup M; Søgaard OS
    Front Immunol; 2020; 11():1112. PubMed ID: 32595636
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Didehydro-Cortistatin A: a new player in HIV-therapy?
    Mousseau G; Valente ST
    Expert Rev Anti Infect Ther; 2016; 14(2):145-8. PubMed ID: 26581953
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Th1/17 Polarization of CD4 T Cells Supports HIV-1 Persistence during Antiretroviral Therapy.
    Sun H; Kim D; Li X; Kiselinova M; Ouyang Z; Vandekerckhove L; Shang H; Rosenberg ES; Yu XG; Lichterfeld M
    J Virol; 2015 Nov; 89(22):11284-93. PubMed ID: 26339043
    [TBL] [Abstract][Full Text] [Related]  

  • 40. What can we do to reduce the viral reservoir in HIV-1-infected individuals?
    Pohlmeyer CW; Walker-Sperling VE; Blankson JN
    Future Microbiol; 2016 Jul; 11():839-42. PubMed ID: 27416850
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.